Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
By
Megan Ziegler
Sesame, salt, and substance. A flagship bake.
Summary
An experimental pill called daraxonrasib has shown promise in helping patients with advanced pancreatic cancer live longer. The drug blocks a mutated protein (KRAS) that drives tumor growth in over 90% of pancreatic cancer cases, a target that had been considered undruggable for decades. Findings were published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting. While not a cure and with effects that eventually wane, the drug represents a significant breakthrough for one of the deadliest cancers.
Key quotes
· 3 pulledThe drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
It's not a cure, as the drug's effects eventually waned, but researchers and other doctors believe...
An experimental pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·1d ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago